Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of “Moderate Buy” from Analysts

Guardant Health, Inc. (NASDAQ:GH) has been given a consensus rating of “Moderate Buy” by the sixteen research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $40.60.

A number of equities analysts have commented on the stock. Piper Sandler boosted their target price on shares of Guardant Health from $30.00 to $34.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Leerink Partners reduced their target price on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. The Goldman Sachs Group boosted their target price on shares of Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Craig Hallum boosted their target price on shares of Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Finally, TD Cowen boosted their target price on shares of Guardant Health from $41.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, August 8th.

Guardant Health Stock Performance

GH stock opened at $35.10 on Thursday. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85. The business has a 50-day moving average price of $24.61 and a 200 day moving average price of $27.14. The company has a market capitalization of $4.34 billion, a P/E ratio of -8.25 and a beta of 1.11. Guardant Health has a 1-year low of $15.81 and a 1-year high of $37.04.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The firm had revenue of $191.48 million during the quarter, compared to the consensus estimate of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.73) earnings per share. As a group, equities research analysts forecast that Guardant Health will post -3.38 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Meghan V. Joyce sold 2,896 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total transaction of $86,590.40. Following the transaction, the director now owns 7,648 shares in the company, valued at $228,675.20. This trade represents a 27.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its position in shares of Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company’s stock valued at $64,754,000 after buying an additional 29,686 shares in the last quarter. Pier Capital LLC lifted its position in shares of Guardant Health by 36.7% during the 3rd quarter. Pier Capital LLC now owns 158,429 shares of the company’s stock valued at $3,634,000 after buying an additional 42,575 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Guardant Health by 188.6% in the 3rd quarter. Wellington Management Group LLP now owns 10,127,528 shares of the company’s stock valued at $232,325,000 after purchasing an additional 6,618,785 shares in the last quarter. Wexford Capital LP lifted its holdings in Guardant Health by 13.0% in the 3rd quarter. Wexford Capital LP now owns 10,081 shares of the company’s stock valued at $231,000 after purchasing an additional 1,158 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its holdings in Guardant Health by 52.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,177,300 shares of the company’s stock valued at $27,007,000 after purchasing an additional 406,500 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.